Neonatal-onset Multisystem Inflammatory Disease
📧 Sign up to get email alerts when something new happens for Neonatal-onset Multisystem Inflammatory Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases)
This clinical trial update describes an ongoing study on the natural history, pathogenesis, and outcomes of autoinflammatory diseases includ…
-
CLINICAL_TRIALS trial_result · 2021-06-10Clinical Trial Update: Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease [Phase 3]
Phase 3 trial of canakinumab for neonatal-onset multisystem inflammatory disease (NOMID/CINCA) was terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2020-09-25Clinical Trial Update: Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase [Phase 3]
Phase 3 study assessing 6-month efficacy and safety of canakinumab in Japanese patients with cryopyrin-associated periodic syndromes, includ…
-
CLINICAL_TRIALS trial_result · 2016-08-03Clinical Trial Update: Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease [Phase 3]
Phase 3 trial assessing efficacy, safety and tolerability of ACZ885 (canakinumab) in pediatric patients with cryopyrin-associated periodic s…
-
CLINICAL_TRIALS trial_result · 2016-03-28Clinical Trial Update: Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients
This registry study assesses clinical outcomes and safety of canakinumab (Ilaris) in patients with cryopyrin-associated periodic syndromes (…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-08-18Clinical Trial Update: Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease [Phase 3]
Phase 3 trial evaluating ACZ885 (canakinumab) for efficacy, safety and tolerability in pediatric patients with Cryopyrin-associated periodic…
-
CLINICAL_TRIALS trial_result · 2011-05-27Clinical Trial Update: Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease [Phase 3]
Phase 3 study evaluating ACZ885 (canakinumab) for efficacy and safety in cryopyrin-associated periodic syndromes, including familial cold au…
-
FDA approval · 2008-02-27FDA Approved: ARCALYST — Original Application (Kiniksa Pharmaceuticals (UK), Ltd.)
FDA approved ARCALYST (rilonacept) from its original Biologics License Application for the treatment of cryopyrin-associated periodic syndro…